Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors - PubMed (original) (raw)

Clinical Trial

Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors

C Gratas et al. Brain Pathol. 1997 Jul.

Abstract

Fas/APO-1 (CD95) is a cell surface receptor that mediates apoptosis when it reacts with Fas ligand (FasL) or Fas antibody. We previously reported that Fas expression is predominantly induced in perinecrotic glioma cells, suggesting that Fas induction is associated with apoptosis and necrosis formation, a histological hallmark of glioblastomas. In this study, we assessed the expression of FasL in 10 glioblastoma cell lines and in 14 astrocytic brain tumors (three low-grade astrocytomas and 11 glioblastomas). Reverse transcriptase (RT)-PCR revealed that all glioblastoma cell lines and primary astrocytic brain tumors express FasL. Immunohistochemically, FasL was predominantly expressed on the plasma membrane of glioma cells. These results suggest that FasL expression is common in human astrocytic brain tumors and may cause apoptosis of glioma cells if Fas expression is induced.

PubMed Disclaimer

Similar articles

• CD95 ligand: lethal weapon against malignant glioma?
  Weller M, Kleihues P, Dichgans J, Ohgaki H. Weller M, et al. Brain Pathol. 1998 Apr;8(2):285-93. doi: 10.1111/j.1750-3639.1998.tb00154.x. Brain Pathol. 1998. PMID: 9546287 Free PMC article. Review.
• Possible involvement of Fas system in the induction of apoptosis in human astrocytic brain tumors.
  Fujita H, Koji T, Kitagawa N, Tsutsumi K, Abe K, Kaminogo M, Shibata S. Fujita H, et al. Cell Mol Neurobiol. 2002 Aug;22(4):393-406. doi: 10.1023/a:1021007503779. Cell Mol Neurobiol. 2002. PMID: 12507389
• Fas ligand expression and depletion of T-cell infiltration in astrocytic tumors.
  Ichinose M, Masuoka J, Shiraishi T, Mineta T, Tabuchi K. Ichinose M, et al. Brain Tumor Pathol. 2001;18(1):37-42. doi: 10.1007/BF02478923. Brain Tumor Pathol. 2001. PMID: 11517972
• Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
  Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY. Saas P, et al. J Clin Invest. 1997 Mar 15;99(6):1173-8. doi: 10.1172/JCI119273. J Clin Invest. 1997. PMID: 9077524 Free PMC article.
• On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
  Greil R, Egle A, Villunger A. Greil R, et al. Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.

Cited by

• Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, and liver damage but accelerates tumour formation in nude mice.
  Chio CC, Wang YS, Chen YL, Lin SJ, Yang BC. Chio CC, et al. Br J Cancer. 2001 Oct 19;85(8):1185-92. doi: 10.1054/bjoc.2001.2055. Br J Cancer. 2001. PMID: 11710833 Free PMC article.
• Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation.
  Perabo FG, Kamp S, Schmidt D, Lindner H, Steiner G, Mattes RH, Wirger A, Pegelow K, Albers P, Kohn EC, von Ruecker A, Mueller SC. Perabo FG, et al. Br J Cancer. 2001 May 18;84(10):1330-8. doi: 10.1054/bjoc.2001.1808. Br J Cancer. 2001. PMID: 11355943 Free PMC article.
• CD95 ligand: lethal weapon against malignant glioma?
  Weller M, Kleihues P, Dichgans J, Ohgaki H. Weller M, et al. Brain Pathol. 1998 Apr;8(2):285-93. doi: 10.1111/j.1750-3639.1998.tb00154.x. Brain Pathol. 1998. PMID: 9546287 Free PMC article. Review.
• FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS.
  Foehr ED, Lorente G, Vincent V, Nikolich K, Urfer R. Foehr ED, et al. J Neurooncol. 2005 Sep;74(3):241-8. doi: 10.1007/s11060-004-7202-x. J Neurooncol. 2005. PMID: 16187021
• Immunotherapy of malignant brain tumors.
  Mitchell DA, Fecci PE, Sampson JH. Mitchell DA, et al. Immunol Rev. 2008 Apr;222:70-100. doi: 10.1111/j.1600-065X.2008.00603.x. Immunol Rev. 2008. PMID: 18363995 Free PMC article. Review.

References

1. 1. Alderson MR, Tough TW, Davis Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH (1995) Fas ligand mediates activation‐induced cell death in human T lymphocytes. J Exp Med 181: 71–77. - PMC - PubMed
2. 1. Barker FG, Davis RL, Chang SM, Prados MD (1996) Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77: 1161–1166. - PubMed
3. 1. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC (1995) A role for CD95 ligand in preventing graft rejection. Nature 377: 630–632. - PubMed
4. 1. Burger PC Scheithauer BW (1994) Tumors of the Central Nervous System. Armed Forces Institute of Pathology: Washington , DC .
5. 1. Cheng J, Liu C, Koopman WJ, Mountz JD (1995) Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol 154: 1239–1245. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal